Deeply undervalued · +57.6% margin of safety
Market outside MC distributionMarket €36.70 vs DCF €86.52 (post-governance, pre-gov €96.14). Even at the 5th-percentile Monte Carlo outcome (€59.00), intrinsic value exceeds today's price by 61%.
What it sells, where it sells
Operating segments — FY25 revenue €2.52B
IFRS 8 reports three geographic operating segments. Modeled as one consolidated segment in the DCF.
Country mix (revenue-weighted)
Quality profile & the two-sided argument
A five-axis read on the DCF's load-bearing assumptions, plus the bull-vs-bear case distilled into anchor bullets.
Quality snowflake (each axis 0–6)
The two-sided case
- Q1 miss is cycle, not break. Q1 2026 organic -1.4% sent shares -13% on April 17; mgmt reaffirmed FY26 guide (2-3% organic, 12.3% margin) and order book at 55.6% of expected FY revenue is exactly on the 4-year average. The miss is a cyclical wobble in a muddle-through year, not a franchise impairment.
- AI dispersion is priced — distinct from the AI-loser case (TMV). At €36.70 vs €86.52 DCF, the market has already taken the 3% organic floor and 13% Y10 margin as central. Unlike TeamViewer where the market prices outright AI-loser scenarios, Ipsos's panel + global footprint + Ipsos.Digital pivot earns the muddle-through tag. The bear (organic -1 to -3%, 8-10% margin) lives in scenarios, not in the base.
- Founder Truchot put real money down at €50-65. DT & Partners aggressively accumulated through 2023-24 — Feb 2024 @ €62.72, Jun 2024 @ €63.15, Aug 2024 @ €55.34 — materially above today's €36.70. Founder stepped down as Chair on health grounds in Feb 2026, named Chairman Emeritus, with internal successor Stoclet and Bpifrance Lac1 (5.82%) as French-state counterweight.
- €100M buyback for cancellation, ~7.7% total shareholder yield. March 2026 program is ~6.7% of share capital, explicitly for cancellation. Share count has fallen 44.25M (2022) → 43.20M (2025) net of all free-share grants. Trading at 7.2× trailing P/E vs 15-year median 12.1×; 4.2× FCF vs 6.8× median.
- ROIC 12-14% across 100+ M&A deals is the operating model. 5-year ROIC band sits 4-6 pts above any plausible WACC. €179M deployed FY2025 (BVA Family + infas, largest since 2018); gross margin 64.2% (2020) → 68.7% (2025) confirms internal-panel scale is real. The reinvestment story isn't broken — the AI overhang is masking it.
- AI displacement of survey research If synthetic data + LLMs displace 30-50% of concept-test / tracking work, organic turns -1 to -3% and margin compresses to 8-10% on volume deleverage. Binary thesis-killer if it lands fast.
- Synthetic AAA vs actual BBB credit gap Engine's synthetic rating sits above the BBB-area implied by the €400M Jan 2025 bond at 3.75%. Override would lift WACC ~12 bp; equity value -2-3%.
- Client concentration in AI-exposed verticals Top consumer-goods + tech-platform clients are themselves AI-disrupted; their research budgets get squeezed first in any cost-cutting wave.
- Founder departure / CEO transition Truchot stepped down Feb 2026 on health grounds; Poitou as new Global CEO is unproven on plan execution after the 2022-25 plan miss. Orderly transition, but execution premium widened.
- FX translation drag Americas is 33% of revenue; Q1 2026 euro appreciation took 5.4% off reported revenue. Sustained EUR strength continues to weigh even when constant-currency is fine.
Thesis & open questions
Investment thesis
- Q1 miss is cycle, not break. Q1 2026 organic -1.4% sent shares -13% on April 17; mgmt reaffirmed FY26 guide (2-3% organic, 12.3% margin) and order book at 55.6% of expected FY revenue is exactly on the 4-year average. The miss is a cyclical wobble in a muddle-through year, not a franchise impairment.
- AI dispersion is priced — distinct from the AI-loser case (TMV). At €36.70 vs €86.52 DCF, the market has already taken the 3% organic floor and 13% Y10 margin as central. Unlike TeamViewer where the market prices outright AI-loser scenarios, Ipsos's panel + global footprint + Ipsos.Digital pivot earns the muddle-through tag. The bear (organic -1 to -3%, 8-10% margin) lives in scenarios, not in the base.
- Founder Truchot put real money down at €50-65. DT & Partners aggressively accumulated through 2023-24 — Feb 2024 @ €62.72, Jun 2024 @ €63.15, Aug 2024 @ €55.34 — materially above today's €36.70. Founder stepped down as Chair on health grounds in Feb 2026, named Chairman Emeritus, with internal successor Stoclet and Bpifrance Lac1 (5.82%) as French-state counterweight.
- €100M buyback for cancellation, ~7.7% total shareholder yield. March 2026 program is ~6.7% of share capital, explicitly for cancellation. Share count has fallen 44.25M (2022) → 43.20M (2025) net of all free-share grants. Trading at 7.2× trailing P/E vs 15-year median 12.1×; 4.2× FCF vs 6.8× median.
- ROIC 12-14% across 100+ M&A deals is the operating model. 5-year ROIC band sits 4-6 pts above any plausible WACC. €179M deployed FY2025 (BVA Family + infas, largest since 2018); gross margin 64.2% (2020) → 68.7% (2025) confirms internal-panel scale is real. The reinvestment story isn't broken — the AI overhang is masking it.
Key debates
Risks to thesis
If synthetic data + LLMs displace 30-50% of concept-test / tracking work, organic turns -1 to -3% and margin compresses to 8-10% on volume deleverage. Binary thesis-killer if it lands fast.
Engine's synthetic rating sits above the BBB-area implied by the €400M Jan 2025 bond at 3.75%. Override would lift WACC ~12 bp; equity value -2-3%.
Top consumer-goods + tech-platform clients are themselves AI-disrupted; their research budgets get squeezed first in any cost-cutting wave.
Truchot stepped down Feb 2026 on health grounds; Poitou as new Global CEO is unproven on plan execution after the 2022-25 plan miss. Orderly transition, but execution premium widened.
Americas is 33% of revenue; Q1 2026 euro appreciation took 5.4% off reported revenue. Sustained EUR strength continues to weigh even when constant-currency is fine.
~3% Middle East declining -4.4% organic in Q1; Americas -4.1% organic on US public-sector weakness. Mgmt-flagged watchpoints, not thesis-breakers individually but they cluster.
10-year forecast
Revenue + FCFF on the left axis; operating margin on the right axis.
Monte Carlo distribution
Mean €78.21 ± €11.90 · P(intrinsic < market) = 0.0% · 1000 iterations (0 failed).
Cost of capital build
| Risk-free rate | 0.04% | implied from CE − β·(ERP+CRP) |
| Mature-market ERP (assumed) | ~6.60% | Damodaran 2026 global |
| Levered β | 0.9969 | |
| Weighted CRP | 0.90% | country mix × per-country |
| Cost of equity | 7.51% | |
| Pre-tax cost of debt | 2.09% | synth rating Aaa/AAA |
| WACC | 5.89% | |
| Terminal growth | 2.00% | |
| Terminal ROIC | 12.00% |
Full year-by-year DCF
| Year | Revenue | Op mgn | EBIT | EBIT(1−t) | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | €2.60B | 12.3% | €321M | €238M | €72M | €165M | €156M |
| 2 | €2.68B | 12.5% | €334M | €247M | €74M | €173M | €154M |
| 3 | €2.76B | 12.6% | €347M | €256M | €77M | €180M | €152M |
| 4 | €2.84B | 12.7% | €360M | €266M | €79M | €188M | €149M |
| 5 | €2.93B | 12.8% | €374M | €277M | €81M | €196M | €147M |
| 6 | €3.01B | 12.9% | €389M | €288M | €84M | €204M | €145M |
| 7 | €3.11B | 13.0% | €404M | €300M | €86M | €213M | €143M |
| 8 | €3.19B | 13.0% | €414M | €308M | €79M | €229M | €144M |
| 9 | €3.26B | 13.0% | €424M | €316M | €71M | €245M | €145M |
| 10 | €3.33B | 13.0% | €433M | €322M | €62M | €260M | €144M |
Methodology & flags
Damodaran FCFF DCF, 10y explicit + perpetuity. R&D capitalisation: OFF · Lease capitalisation: OFF · Failure-rate adjustment: OFF · ESO subtraction: OFF.